Pseudoephedrine - Revision history

MDElliottMD: parser-claude: Pseudoephedrine MedTemplate refill, Top 300 stub upgrade

2026-05-23T07:34:43Z

parser-claude: Pseudoephedrine MedTemplate refill, Top 300 stub upgrade

← Older revision		Revision as of 07:34, 23 May 2026
Line 1:		Line 1:
	{{MedTemplate		{{MedTemplate
	\| generic = Pseudoephedrine		\| generic = Pseudoephedrine (hydrochloride; sulfate)
	\| brand = Sudafed		\| brand = Sudafed (IR, 12-hour, 24-hour); many combination products including Claritin-D, Allegra-D, Zyrtec-D, Mucinex-D
	\| structure =		\| structure =
	\| classes = ~~Stimulant~~, ~~Decongestant~~		\| classes = [[:Category:Decongestants\|Decongestant]], [[:Category:Sympathomimetics\|Sympathomimetic (indirect-acting)]]
	\| ~~mechanism = Indirect sympathomimetic~~		\| uses = <vote slug="nasal-congestion-cold-use">Nasal congestion from common cold (OTC, FDA)</vote>, <vote slug="allergic-rhinitis-congestion-use">Allergic rhinitis nasal congestion (OTC, FDA)</vote>, <vote slug="sinusitis-congestion-use">Acute sinusitis nasal congestion (OTC, FDA)</vote>, <vote slug="eustachian-tube-congestion-use">Eustachian tube congestion (off-label)</vote>
	\| uses =		\| starting_dose = IR: 60 mg PO every 4-6 hours. 12-hour ER: 120 mg PO every 12 hours. 24-hour ER: 240 mg PO once daily. Pediatric: weight-based
	\| starting_dose =		\| preparations = IR tablets 30, 60 mg; 12-hour ER tablets 120 mg; 24-hour ER tablets 240 mg; oral liquid; multiple combination products with antihistamines, NSAIDs, or expectorants
	\| preparations =		\| fda_max = 240 mg/day
	\| fda_max =		\| pill_id =
	\| routes =		\| routes = Oral
	\| onset =		\| onset = 30-60 minutes
	\| duration =		\| duration = 4-6 hours (IR); 12-24 hours (ER)
	\| halflife =		\| halflife = 9-16 hours (pH-dependent: acidic urine shortens, alkaline urine substantially extends)<ref name="sudafed-monograph">FDA OTC Monograph for Nasal Decongestants. https://www.accessdata.fda.gov/scripts/cder/ob/ (reference for the IR and ER pseudoephedrine formulations)</ref>
	\| bioavailability =		\| bioavailability = ~90% (oral, low first-pass)<ref name="sudafed-monograph" />
	\| pregnancy =		\| pregnancy = Some controversial signal for first-trimester gastroschisis association in observational studies; limited use is generally considered acceptable after the first trimester.{{citation needed}}
	\| legal =		\| legal = '''[[USLegal:Behind-the-counter\|Behind-the-counter]] in US''' under the Combat Methamphetamine Epidemic Act 2005: purchase restricted to ≤3.6 g/day and ≤9 g/30 days, with photo ID, logbook signature, and quantity logging required. Several states schedule higher than federal
	\| ~~intro =~~		\| mechanism = <vote slug="pseudoephedrine-mech-claim">Indirect-acting sympathomimetic. Taken up by adrenergic nerve terminals where it displaces stored norepinephrine into the synaptic cleft via vesicular monoamine transporter activity. Peripheral α1- and β-adrenergic receptor stimulation produces vasoconstriction in nasal mucosa (the decongestant effect, the principal clinical action). Central sympathomimetic effects (mild insomnia, restlessness, anxiety) are substantially less than amphetamines because pseudoephedrine penetrates the CNS poorly compared to amphetamine-class agents.</vote> Cardiovascular adverse effects (elevated blood pressure, tachycardia, occasional arrhythmia) are the principal safety concern; avoid in uncontrolled hypertension and severe coronary artery disease. Urinary retention in benign prostatic hyperplasia is a common counseling point<ref name="sudafed-monograph" />.
	\| ~~pharmacokinetics~~ =
	~~\| pharmacodynamics~~ =
	~~\| indications =~~
	~~\| dosing =~~
	\| effects =
	~~\| interactions =~~ <~~pharmaInteractions~~/>
	~~\| pregnancy_details =~~
	~~\| monitoring =~~
	\| counseling =
	~~\| anecdotes =~~
	~~\| seealso =~~
	~~\| references~~ =
	}}		}}

			== References ==
			<references />

	[[Category:~~Psychostimulants~~]]		[[Category:Decongestants]]
	[[Category:~~Psychostimulants]]~~		[[Category:Sympathomimetics]]
	~~[[Category:Amphetamines~~]]

MDElliottMD: Recategorize: Stimulants -> Psychostimulants

2026-05-17T10:51:04Z

Recategorize: Stimulants -> Psychostimulants

← Older revision		Revision as of 10:51, 17 May 2026
Line 32:		Line 32:


	[[Category:~~Stimulants~~]]		[[Category:Psychostimulants]]
	[[Category:Psychostimulants]]		[[Category:Psychostimulants]]
	[[Category:Amphetamines]]		[[Category:Amphetamines]]

MDElliottMD: Recategorize: Stimulants & Wake-Promoting Agents -> Stimulants

2026-05-17T10:45:17Z

Recategorize: Stimulants & Wake-Promoting Agents -> Stimulants

← Older revision		Revision as of 10:45, 17 May 2026
Line 32:		Line 32:


	[[Category:Stimulants ~~& Wake-Promoting Agents~~]]		[[Category:Stimulants]]
	[[Category:Psychostimulants]]		[[Category:Psychostimulants]]
	[[Category:Amphetamines]]		[[Category:Amphetamines]]

MDElliottMD: Comprehensive categorization: +Amphetamines

2026-05-15T18:42:03Z

Comprehensive categorization: +Amphetamines

← Older revision		Revision as of 18:42, 15 May 2026
Line 34:		Line 34:
	[[Category:Stimulants & Wake-Promoting Agents]]		[[Category:Stimulants & Wake-Promoting Agents]]
	[[Category:Psychostimulants]]		[[Category:Psychostimulants]]
			[[Category:Amphetamines]]

MediaWiki default: Assign pharmacological categories from List_of_CNS-active_medicines

2026-05-14T15:06:56Z

Assign pharmacological categories from List_of_CNS-active_medicines

← Older revision		Revision as of 15:06, 14 May 2026
Line 31:		Line 31:
	}}		}}


			[[Category:Stimulants & Wake-Promoting Agents]]
	[[Category:Psychostimulants]]		[[Category:Psychostimulants]]

MDElliottMD: Pharmacopedia: add

2026-05-14T03:31:07Z

Pharmacopedia: add <pharmaInteractions/>

← Older revision		Revision as of 03:31, 14 May 2026
Line 22:		Line 22:
	\| dosing =		\| dosing =
	\| effects =		\| effects =
	\| interactions =		\| interactions = <pharmaInteractions/>
	\| pregnancy_details =		\| pregnancy_details =
	\| monitoring =		\| monitoring =

MDElliottMD: Pharmacopedia: remove contraindications parameter

2026-05-14T02:40:48Z

Pharmacopedia: remove contraindications parameter

← Older revision		Revision as of 02:40, 14 May 2026
Line 22:		Line 22:
	\| dosing =		\| dosing =
	\| effects =		\| effects =
	~~\| contraindications =~~
	\| interactions =		\| interactions =
	\| pregnancy_details =		\| pregnancy_details =

MDElliottMD: Added empty fda_max parameter to MedTemplate call

2026-05-13T02:32:45Z

Added empty fda_max parameter to MedTemplate call

← Older revision		Revision as of 02:32, 13 May 2026
Line 8:		Line 8:
	\| starting_dose =		\| starting_dose =
	\| preparations =		\| preparations =
			\| fda_max =
	\| routes =		\| routes =
	\| onset =		\| onset =
Line 32:		Line 33:

	[[Category:Psychostimulants]]		[[Category:Psychostimulants]]

MDElliottMD: Expand stub to full MedTemplate parameter set

2026-05-13T01:00:00Z

Expand stub to full MedTemplate parameter set

@@ Line 1: / Line 1: @@
 {{MedTemplate
-| generic           = Pseudoephedrine
+| generic            = Pseudoephedrine
-| brand             = Sudafed
+| brand              = Sudafed
-| classes           = Stimulant, Decongestant
+| structure          =
-| mechanism         = Indirect sympathomimetic
+| classes            = Stimulant, Decongestant
 }}
 [[Category:Psychostimulants]]

MDElliottMD: Auto-created stub

2026-05-13T00:00:00Z

Auto-created stub

New page

{{MedTemplate
| generic = Pseudoephedrine
| brand = Sudafed
| classes = Stimulant, Decongestant
| mechanism = Indirect sympathomimetic
}}
[[Category:Psychostimulants]]